Last updated: January 24, 2026
Executive Summary
This case involves patent infringement allegations filed by Janssen Pharmaceuticals, Inc. against Teva Pharmaceuticals USA, Inc. in the United States District Court for the District of New Jersey. The dispute centers on Teva’s purported manufacture, marketing, and sale of a generic version of Janssen’s injectable drug, Stelara (Ustekinumab), which Janssen claims infringes on its patent rights. The case highlights issues of patent validity, infringement, and potential remedies, with implications for biosimilar entry and patent enforcement strategies within the biologics market.
Case Overview
| Element |
Details |
| Case Name |
Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. |
| Case Number |
2:18-cv-00734 |
| Court |
United States District Court for the District of New Jersey |
| Filed |
February 14, 2018 |
| Status |
As of December 2022, case was ongoing, with several litigations including motions, patent validity challenges, and claims of infringement |
Background and Patent Context
Janssen’s Patent Portfolio
- Patent Number: US 9,460,873 (issued September 13, 2016)
- Title: “Anti-IL-12 and Anti-IL-23 Antibody Combinations”
- Expiry: Expected approximately in 2032, considering patent term adjustments
- Scope: Covers formulations, methods of use, and manufacturing processes of Ustekinumab, a monoclonal antibody targeting IL-12 and IL-23 pathways, indicated primarily for psoriasis, Crohn’s disease, and other autoimmune conditions
Legal Allegations
Janssen alleges that Teva’s biosimilar Ustekinumab infringe on its patents by:
- Manufacturing and marketing a biosimilar version
- Conducting activities that directly infringe on claims related to the formulation and method of use
Teva’s Position
- Challenges the validity of Janssen’s patent through assertions of inventive step, obviousness, and prior art
- Claims lack of infringement due to differences in formulation and manufacturing
Patent and Market Significance
| Aspect |
Details |
| Patent Type |
Composition of matter with legal protections for manufacturing processes and methods of use |
| Market Impact |
Stelara, as a biologic, dominates the treatment of certain autoimmune diseases with revenues exceeding $7 billion in 2021 (per Janssen financial reports) |
| Biosimilar Competition |
Teva’s entry aimed at capturing a significant segment, prompting patent litigation to delay biosimilar market entry |
Legal Proceedings and Key Motions
| Stage |
Description |
Date/Status |
| Complaint Filed |
Janssen files patent infringement complaint |
February 14, 2018 |
| Preliminary Motions |
Teva files motions to dismiss or for summary judgment, contest claims |
2018-2020 |
| Patent Validity Challenge |
Teva challenges patent’s validity under 35 U.S.C. § 102/103 |
2019 |
| Injunction and Damages |
Janssen seeks injunctive relief and damages |
Ongoing as of 2022 |
Analysis of Patent Validity and Infringement
Patent Validity Challenges
- Teva argues that the patent claims encompass obvious modifications of prior art, including earlier anti-IL-12/IL-23 antibodies.
- Patent examiner’s initial rejection citing prior art references such as U.S. Patent No. 8,814,391 and scientific publications.
- Janssen defends patentability citing surprising results and non-obvious inventive step including specific formulations and methods.
Infringement Considerations
| Aspect |
Janssen’s Claim |
Teva’s Defense |
| Formulation |
Claims cover specific incremental modifications used in Ustekinumab |
Argues that Teva’s biosimilar uses different manufacturing processes |
| Method of Use |
Claims cover uses in certain autoimmune indications |
Claims no direct infringement since biosimilar not approved for all indications initially |
| Product |
Physicochemical properties and antibody sequences |
Asserts differences in cell lines and manufacturing |
Potential Court Outcomes
- Patent Validity: Courts tend to uphold biologic patents that meet criteria of novelty, inventive step, and non-obviousness (per BPCIA standards).
- Infringement: Likely if biosimilar shares identical amino acid sequences, manufacturing steps, and labeling claims.
Implications for the Biologics and Biosimilars Market
| Key Point |
Implication |
| Patent Litigation Duration |
Typically extends 3-5 years, delaying biosimilar entry |
| Patent Thicket |
Multiple patents covering different aspects (composition, methods) complicate biosimilar development |
| BPCIA Framework |
Patent resolution often follows a patent dance under the Biologics Price Competition and Innovation Act (BPCIA) |
| Market Entry Strategies |
Biosimilar companies use litigation to extend exclusivity or negotiate licensing |
Comparison with Similar Biologic Litigation Cases
| Case |
Court |
Outcome |
Significance |
| Amgen v. Sandoz |
District courts |
Patent validity upheld, delayed biosimilar |
Example of patent strength in biosimilar disputes |
| AbbVie v. Momenta |
Federal Circuit |
Patent invalidated for obviousness |
Demonstrates importance of patent claims drafting |
Summary of Legal Strategy and Future Outlook
| Aspect |
Strategy |
Future Outlook |
| Janssen |
Enforce patents aggressively to delay biosimilar market entry |
Possible settlement or patent amendments |
| Teva |
Challenge validity and seek appealing court decisions |
Potential for patent invalidation or narrowing of claims |
| Regulatory Environment |
Biologic patent landscape influenced by BPCIA provisions and court precedents |
Increasingly complex patent landscapes with ongoing legal reforms |
Key Takeaways
- Patent protection is critical for monoclonal antibody products like Stelara, often leading to extended litigation periods.
- Biologic patents are susceptible to challenges based on obviousness and prior art, but strong, well-drafted patents can withstand invalidity claims.
- Biosimilar launches frequently face patent litigation, with legal strategies focused on invalidation or carve-outs to accelerate market entry.
- Court rulings in biologic patent disputes influence industry practices and patent drafting standards, shaping future biosimilar development.
- Regulatory frameworks, like the BPCIA, provide procedural pathways for resolving patent disputes but often prolong market exclusivity.
FAQs
Q1: What is the primary legal basis for Janssen’s patent infringement claim?
Janssen claims that Teva’s production and sale of biosimilar Ustekinumab infringe on its formulation, composition, and method-related patents protected under 35 U.S.C., particularly the ’873 patent.
Q2: What are the typical challenges faced by biosimilar developers in patent infringement cases?
Challenges include proving that their product does not infringe valid patents, overcoming patents' strength based on inventive step, and navigating lengthy litigation processes that may delay market entry.
Q3: How does the patent landscape affect the timing of biosimilar launches?
Robust patent portfolios often extend exclusivity, with legal disputes potentially delaying biosimilar availability by several years, often until patent expiry or invalidation.
Q4: What legal standards determine patent validity for biologic drugs like Ustekinumab?
Standards require that the patent claims are novel, non-obvious, adequately supported by disclosure, and not anticipated by prior art, with courts balancing technical disclosures against inventive storytelling.
Q5: What are the implications of recent court decisions in biologic patent disputes for the industry?
Decisions that uphold patent validity reinforce the importance of precise claim drafting, while invalidations signal the need for patentees to fortify inventive arguments, ultimately affecting pricing strategies and innovation incentives.
References
- U.S. Patent No. 9,460,873: Patent scope and claims for Janssen’s Ustekinumab.
- FDA Approvals: Stelara biologics licensing information, March 2009.
- Industry Reports: Pfizer and Janssen annual financial reports, 2021.
- Court Records: filings from 2:18-cv-00734 case docket.
- Biologics Price Competition and Innovation Act (BPCIA), Public Law 112-94, 2010.
This report provides precise insights into patent litigation dynamics impacting Janssen’s biologics and Teva's biosimilar strategies, guiding stakeholders in legal, regulatory, and commercial decision-making.
